Cancer News and Research

Latest Cancer News and Research

New targeted therapy shows positive results in patients with lung cancer

A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

2 Nov 2010

Eye transformer impacts JAK/STAT-signaling pathway response with microbial challenge

Scientists are keeping their eye on a new discovery published in the November 2011 print issue of the FASEB Journal (http://www.fasebj.org) that explains what causes some genes to go out of control. Scientists have identified a "cellular switch," called eye transformer, that controls the flow of information from chemical signals outside of the cell to genes in the cell nucleus.

2 Nov 2010

Brain MRI could predict duration of stroke onset

Magnetic resonance imaging (MRI) of the brain could expand the number of stroke patients eligible for a potentially life-saving treatment, according to a new study, published online and in the December issue of the journal Radiology.

2 Nov 2010

Effective treatment for brain cancer in daffodils

When looking for new ways to treat aggressive brain cancers, an international team of scientists turned a new leaf and "discovered" the lowly daffodil. A new research study published in the November 2010 print issue of The FASEB Journal (http://www.fasebj.org) offers hope that a natural compound found in daffodil bulbs, called narciclasine, may be a powerful therapeutic against biologically aggressive forms of human brain cancers.

2 Nov 2010

Elekta awarded delivery of three Leksell Gamma Knife systems to Chinese hospitals

In winning a tender to deliver three Leksell Gamma Knifeâ models to hospitals in China, Elekta will help more cancer patients receive the therapy they need. The agreement also helps Elekta increase its leading market position in China.

From Elekta 2 Nov 2010

NSAIDs drugs prevent colon cancer: Research

Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent colon cancer by triggering diseased stem cells to self-destruct, according to researchers at the University of Pittsburgh Cancer Institute (UPCI) and the University of Pittsburgh School of Medicine.

2 Nov 2010

$Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients$

Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients

When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.

2 Nov 2010

Parents need to protect time children need to sleep

We all know that pulling all-nighters, being overly caffeinated and overly stimulated have become a part of college life, but the reality is that even as school-age children are dealing with these scenarios.

2 Nov 2010

PITs compounds induce cell death and limit tumor growth

A class of compounds that interferes with cell signaling pathways may provide a new approach to cancer treatment, according to a study published online this week in the Proceedings of the National Academy of Sciences (PNAS) Early Edition. The compounds, called PITs (non-phosphoinositide PIP3 inhibitors), limited tumor growth in mice by inducing cell death.

2 Nov 2010

New REACT medical trial for early diagnosis of lung cancer

Physicians at El Camino Hospital are starting a medical trial called REACT that they hope may give doctors a new and cost-effective tool for early diagnosis of lung cancer, the deadliest of the common cancers.

2 Nov 2010

Einstein College's new website features latest information on aging research

Albert Einstein College of Medicine of Yeshiva University has launched SuperAgers.com, a new website that features the latest information on more than a decade of aging research at Einstein.

2 Nov 2010

Research on AID enzyme could improve therapy for lymphoma, leukemia

A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.

2 Nov 2010

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.

2 Nov 2010

Arrayit sells third advanced microarray manufacturing system to UT Southwestern

Arrayit Corporation announced today that it has sold a third advanced microarray manufacturing system to the University of Texas Southwestern Medical Center at Dallas. The NanoPrint LM60 Microarrayer equipped with Arrayit's Patented Microarray Manufacturing Technology (US Patent 6,101,946) is a computer-driven robotic microarray manufacturing system that enables the screening of 1.5 million lead therapeutic compounds per run, and the NanoPrint LM210 enables more than 5 million.

2 Nov 2010

Novel technology using quantum dots increases drug uptake in lung injury

Researchers at the University at Buffalo have developed a novel technology using quantum dots that is expected to have major implications for research and treatment of tuberculosis, as well as other inflammatory lung diseases.

2 Nov 2010

EMA issues Scientific Advice to Genta's clinical development plan for tesetaxel in patients with gastric cancer

Genta Incorporated today announced that the Company has received Scientific Advice from the European Medicines Agency (EMA) on the Company's clinical development plan for tesetaxel in patients with advanced gastric cancer, which includes a pivotal, randomized, controlled, Phase 3 trial.

2 Nov 2010

LCA releases 2010 National Report Card on Lung Cancer

Today, Lung Cancer Alliance (LCA) released its Annual National Report Card on Lung Cancer, an overall assessment of the nation's response to the continuing high mortality of lung cancer, the leading cancer killer.

2 Nov 2010

HHS awards CTI $977,917 in grants under Therapeutic Discovery Tax Credit program

Cell Therapeutics, Inc. today announced that it has been awarded $977,917 in grants under the Therapeutic Discovery Tax Credit program that was enacted under the U.S. government's Patient Protection and Affordable Care Act. The program targets projects that show potential to produce new therapies, address unmet medical needs, reduce the long-term growth of health care costs and advance the goal of curing cancer.

2 Nov 2010

PPACA program provides $733,438 grant to Inovio

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has received a $733,438 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA).

2 Nov 2010

New microfluidic in vitro kinase radioassay improves efficiency to detect cancer growth

Inappropriate growth and survival signaling, which leads to the aberrant growth of cancer cells, is a driving force behind tumors. Much of current cancer research focuses on the kinase enzymes whose mutations are responsible for such disregulated signaling, and many successful molecularly targeted anti-cancer therapeutics are directed at inhibiting kinase activity.

2 Nov 2010